Nov. 5, 2013
/PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering to sell an aggregate of 25 million shares of its common stock under Discovery Labs' previously filed registration statement declared effective by the Securities and Exchange Commission on
June 21, 2011
. Each share was issued and sold at a public offering price of
Discovery Labs has received net proceeds of approximately
, after deducting underwriting discount and other estimated fees and expenses related to the offering. The net proceeds will be used primarily (i) to support the commercial introduction of SURFAXIN
drug product, (ii) to advance the AEROSURF
development program, including a planned phase 2 clinical program and (iii) for general corporate purposes.
& Co. acted as joint bookrunning managers for the offering, Lazard Capital Markets LLC acted as co-lead manager and Roth Capital Partners, LLC acted as co-manager. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission web site at
, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street
, Suite 3700,
San Francisco, California
94104 or via telephone at (415) 364-2500 or from
& Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Discovery Laboratories, Inc., nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.